Myeloma Treatment Choices: FAQs
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

Released: August 24, 2021

Expiration: August 23, 2022

Paul G. Richardson
Paul G. Richardson, MD
Nina Shah
Nina Shah, MD
Peter Michael Voorhees
Peter Michael Voorhees, MD

Activity

Progress
1
Course Completed

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:

  • Treatment after first relapsed
  • Optimal use of CAR T-cell therapy
  • When to use selinexor and belantamab mafodotin
  • COVID-19 vaccinations for patients with myeloma